Latest Revenue Growth News

Centrepoint Alliance reported a 13.5% revenue increase and a 30.6% rise in pre-tax profit for the year ended June 2025, yet net profit after tax fell by 33.7%. The company maintained its final dividend at 1.75 cents per share.

Intelligent Monitoring Group reports robust FY2025 financials, completes a strategic acquisition, and issues new shares following warrant exercises, signaling a confident growth trajectory.

Felix Group Holdings Ltd has launched a capped $1 million Share Purchase Plan (SPP) offering eligible shareholders a discounted entry to support its strategic acquisition of Nexvia Pty Ltd and fuel growth initiatives. This retail-focused SPP complements a larger institutional placement as Felix aims to expand its enterprise software footprint.

Mader Group Limited has reported a solid 13% increase in both revenue and profit for the 2025 financial year, accompanied by a notable rise in dividends.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.